<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02969928</url>
  </required_header>
  <id_info>
    <org_study_id>AmxMetClmCFA</org_study_id>
    <nct_id>NCT02969928</nct_id>
  </id_info>
  <brief_title>Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis</brief_title>
  <official_title>Full-mouth Periodontal Debridement Associated With Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis: Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Estadual Paulista Júlio de Mesquita Filho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Estadual Paulista Júlio de Mesquita Filho</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the clinical outcomes of full-mouth ultrasonic debridement&#xD;
      combined with clarithromycin or amoxicillin + metronidazole association for the treatment of&#xD;
      generalized aggressive periodontitis (GAgP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study methodology is according to CONSORT-STATEMENT 2010 for randomized controlled&#xD;
      clinical trials.&#xD;
&#xD;
      Study Design&#xD;
&#xD;
      The study is designed as a prospective, interventional, parallel, triple blind, randomized,&#xD;
      controlled clinical trial aimed to assess the clinical outcomes of full-mouth ultrasonic&#xD;
      debridement combined with clarithromycin or amoxicillin + metronidazole association for the&#xD;
      treatment of generalized aggressive periodontitis (GAgP). The study was approved by Institute&#xD;
      of Science and Technology's (ICT - State University of São Paulo) Ethics Committee (protocol&#xD;
      1.079.307).&#xD;
&#xD;
      Source of data&#xD;
&#xD;
      The population of this study will be recruited among patients referred to the Science and&#xD;
      Technology Institute - ICT- São José dos Campos, College of Dentistry. Patients will fill a&#xD;
      healthy history questionnaire to ensure that they are medically qualified for participate in&#xD;
      this study. Based on the power calculation for this study, 44 subjects divided into two&#xD;
      groups will be needed to achieve 80% power to detect a 0.8 mm difference in the clinical&#xD;
      attachment level (CAL) of patients.&#xD;
&#xD;
      Clinical Parameters&#xD;
&#xD;
      All clinical parameters will be assessed by a single blinded, trained and calibrated examiner&#xD;
      (CFA) before periodontal therapy (baseline) and at 3 and 6 months after using a manual probe.&#xD;
      Measurements will be done at six sites per tooth (mesiobuccal, buccal, disto-buccal,&#xD;
      distolingual, lingual, and mesiolingual) in all teeth, except third molars.&#xD;
&#xD;
      The following clinical parameters will be evaluated: 1) Full-mouth plaque index (FMPI); 2)&#xD;
      Bleeding on probing (BoP); 3) Probing depth (PD): distance from the bottom of sulcus/pocket&#xD;
      to gingival margin; 4) Gingival recession (GM): distance from the free gingival margin to&#xD;
      cement-enamel junction (CEJ); 5) Clinical attachment level (CAL): distance from bottom of&#xD;
      sulcus/pocket to the CEJ. The CEJ will be identified by careful probe on cervical area.&#xD;
&#xD;
      Calibration and Randomization&#xD;
&#xD;
      Initially, a total of ten patients presenting with GAgP will be selected. The designated&#xD;
      examiner (CFA) will measure CAL and PD in all patients twice within 24 hours, with an&#xD;
      interval of ≥ 1 hour between examinations. Then, the measures will be submitted to intraclass&#xD;
      correlation test and the examiner will be judged calibrated if reaches 90% agreement.&#xD;
&#xD;
      Patients will be allocated into two groups according to a computer-generated list. The&#xD;
      allocation will be implemented by an investigator (NCCS) who was not directly involved in the&#xD;
      examination or treatment procedures. All medication will be prepared and encased in identical&#xD;
      opaque coded bottles by a manipulation pharmacy on São José dos Campos/São Paulo.&#xD;
&#xD;
      Treatment Protocols&#xD;
&#xD;
      All patients will be treated with periodontal therapy through of the one-stage, full mouth,&#xD;
      ultrasonic debridement (FMUD). In a single session, patients will receive local anesthesia&#xD;
      and periodontal debridement with ultrasound equipment (Cavitron - Dentsply EUA) and&#xD;
      subgingival tips (UI25KSF10S, Hu-Friedy). All diseased sites will be instrumented in this one&#xD;
      session. The debridement session will be performed by a single experienced and trained&#xD;
      periodontist (MPS), different from the examiner. Immediately before the mechanical therapy,&#xD;
      patients will be allocated in one of the two treatment protocols:&#xD;
&#xD;
        1. Clarithromycin (CLM) group (n = 22): FMUD + CLM 500 mg bid, for 7 days and&#xD;
&#xD;
        2. Amoxicillin (AMX) + metronidazole (MET) group (n = 22): FMUD + (AMX 500 mg tid + MET 400&#xD;
           mg tid, both for 7 days.&#xD;
&#xD;
      All patients will start taking the pills immediately before of the FMUD session.&#xD;
&#xD;
      Compliance and Adverse Effects&#xD;
&#xD;
      After 7 days of periodontal treatment, patients will be asked to return any medication not&#xD;
      taken and/or the empty bottles. The number of pills not taken by the subject will be&#xD;
      documented. Moreover, patients will be instructed to return a self-report form filled about&#xD;
      any possible adverse effects in order to help evaluate their adherence to the systemic&#xD;
      antimicrobial regimen.&#xD;
&#xD;
      Statistical analysis&#xD;
&#xD;
      Mean and standard deviation will be calculated for each parameter. The normal distribution of&#xD;
      the data will be analyzed by Shapiro-Wilk test. Data from clinical measurements will be&#xD;
      subjected to analysis of variance (repeated measures) for inter and intra-group comparison.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinical Attachment Level (CAL)</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>Evaluate the difference between baseline and 6 months CAL measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Probing Depth (PB)</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>Evaluate the difference between baseline and 6 months PB measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bleeding on Probe (BoP)</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <description>Evaluate the difference between baseline and 6 months BoP measures.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Compliance</measure>
    <time_frame>One week post treatment</time_frame>
    <description>After 7 days of periodontal treatment, patients will be asked to return any medication not taken and/or the empty bottles. The number of pills not taken by the subject will be documented in order to evaluate compliance.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Effects That May be Related to Antibiotic Treatment</measure>
    <time_frame>One week post treatment</time_frame>
    <description>Patients will be instructed to fill a self-report form about any possible adverse effects in order to help evaluate their adherence to the systemic antimicrobial regimen.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Aggressive Periodontitis</condition>
  <arm_group>
    <arm_group_label>Amoxicillin and Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Full-mouth ultrasonic debridement</intervention_name>
    <description>Full-mouth ultrasonic debridement will be performed in order to treat diseased sites</description>
    <arm_group_label>Amoxicillin and Metronidazole</arm_group_label>
    <arm_group_label>Clarithromycin</arm_group_label>
    <other_name>Periodontal debridement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Administration of Clarithromycin 500mg bid for 7 days</description>
    <arm_group_label>Clarithromycin</arm_group_label>
    <other_name>Biaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Administration of Amoxicillin 500mg tid for 7 days.</description>
    <arm_group_label>Amoxicillin and Metronidazole</arm_group_label>
    <other_name>Amoxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Administration of Metronidazole 400mg tid for 7 days.</description>
    <arm_group_label>Amoxicillin and Metronidazole</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. diagnosis of GAgP (AAP, 1999);&#xD;
&#xD;
          2. presence of ≥20 teeth;&#xD;
&#xD;
          3. presence of ≥ 6 sites presenting PD ≥ 5mm with bleeding on probing (BOP) and ≥2 sites&#xD;
             with PD ≥7mm (including incisors and first molars, in addition to other two&#xD;
             non-contiguous teeth);&#xD;
&#xD;
          4. good general health;&#xD;
&#xD;
          5. ≤ 35 years old; and&#xD;
&#xD;
          6. agree to participate in the study and sign a written informed consent. All subjects&#xD;
             will be individually informed about the objectives, probable risks and benefits of the&#xD;
             protocol treatment (according to Resolution nº196 of October 1996 and to the&#xD;
             Professional Code of Dental Ethics - 179/93).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. pregnancy or lactating;&#xD;
&#xD;
          2. suffer from any systemic disease (e.g. cardiovascular disorders, diabetes, blood&#xD;
             dyscrasias, immunodeficiency, etc) which could alter the course of periodontal&#xD;
             disease;&#xD;
&#xD;
          3. took antimicrobials in the previous 6 months;&#xD;
&#xD;
          4. taking long-term anti-inflammatory drugs;&#xD;
&#xD;
          5. previous periodontal treatment within the last 12 months;&#xD;
&#xD;
          6. smokers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro P Santamaria, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>College of Dentistry - São José dos Campos, Sao Paulo State University</name>
      <address>
        <city>São José dos Campos</city>
        <state>SP</state>
        <zip>12245-310</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Pradeep AR, Kathariya R. Clarithromycin, as an adjunct to non surgical periodontal therapy for chronic periodontitis: a double blinded, placebo controlled, randomized clinical trial. Arch Oral Biol. 2011 Oct;56(10):1112-9. doi: 10.1016/j.archoralbio.2011.03.021. Epub 2011 May 6.</citation>
    <PMID>21529775</PMID>
  </reference>
  <reference>
    <citation>Mestnik MJ, Feres M, Figueiredo LC, Duarte PM, Lira EA, Faveri M. Short-term benefits of the adjunctive use of metronidazole plus amoxicillin in the microbial profile and in the clinical parameters of subjects with generalized aggressive periodontitis. J Clin Periodontol. 2010 Apr;37(4):353-65. doi: 10.1111/j.1600-051X.2010.01538.x.</citation>
    <PMID>20447259</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <results_first_submitted>May 4, 2020</results_first_submitted>
  <results_first_submitted_qc>August 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 7, 2020</results_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</investigator_affiliation>
    <investigator_full_name>Mauro Pedrine Santamaria</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Full-mouth ultrasonic debridement</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Amoxicillin</keyword>
  <keyword>Metronidazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Aggressive Periodontitis</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amoxicillin and Metronidazole</title>
          <description>In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Amoxicillin: Administration of Amoxicillin 500mg tid for 7 days.&#xD;
Metronidazole: Administration of Metronidazole 400mg tid for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Clarithromycin</title>
          <description>In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Clarithromycin: Administration of Clarithromycin 500mg bid for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amoxicillin and Metronidazole</title>
          <description>In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Amoxicillin: Administration of Amoxicillin 500mg tid for 7 days.&#xD;
Metronidazole: Administration of Metronidazole 400mg tid for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Clarithromycin</title>
          <description>In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Clarithromycin: Administration of Clarithromycin 500mg bid for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Clinical Attachment Level (CAL)</title>
        <description>Evaluate the difference between baseline and 6 months CAL measures.</description>
        <time_frame>Baseline, 3 and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin and Metronidazole</title>
            <description>In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Amoxicillin: Administration of Amoxicillin 500mg tid for 7 days.&#xD;
Metronidazole: Administration of Metronidazole 400mg tid for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin</title>
            <description>In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Clarithromycin: Administration of Clarithromycin 500mg bid for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Attachment Level (CAL)</title>
          <description>Evaluate the difference between baseline and 6 months CAL measures.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="0.7"/>
                    <measurement group_id="O2" value="3.62" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.5"/>
                    <measurement group_id="O2" value="3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.5"/>
                    <measurement group_id="O2" value="3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Probing Depth (PB)</title>
        <description>Evaluate the difference between baseline and 6 months PB measures.</description>
        <time_frame>Baseline, 3 and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin and Metronidazole</title>
            <description>In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Amoxicillin: Administration of Amoxicillin 500mg tid for 7 days.&#xD;
Metronidazole: Administration of Metronidazole 400mg tid for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin</title>
            <description>In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Clarithromycin: Administration of Clarithromycin 500mg bid for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Probing Depth (PB)</title>
          <description>Evaluate the difference between baseline and 6 months PB measures.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="0.6"/>
                    <measurement group_id="O2" value="3.41" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.3"/>
                    <measurement group_id="O2" value="2.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.3"/>
                    <measurement group_id="O2" value="2.7" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bleeding on Probe (BoP)</title>
        <description>Evaluate the difference between baseline and 6 months BoP measures.</description>
        <time_frame>Baseline, 3 and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin and Metronidazole</title>
            <description>In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Amoxicillin: Administration of Amoxicillin 500mg tid for 7 days.&#xD;
Metronidazole: Administration of Metronidazole 400mg tid for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin</title>
            <description>In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Clarithromycin: Administration of Clarithromycin 500mg bid for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bleeding on Probe (BoP)</title>
          <description>Evaluate the difference between baseline and 6 months BoP measures.</description>
          <units>% of sites with bleeding on probe</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4" spread="17.4"/>
                    <measurement group_id="O2" value="43.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="9.3"/>
                    <measurement group_id="O2" value="24.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="8.3"/>
                    <measurement group_id="O2" value="23.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compliance</title>
        <description>After 7 days of periodontal treatment, patients will be asked to return any medication not taken and/or the empty bottles. The number of pills not taken by the subject will be documented in order to evaluate compliance.</description>
        <time_frame>One week post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin and Metronidazole</title>
            <description>In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Amoxicillin: Administration of Amoxicillin 500mg tid for 7 days.&#xD;
Metronidazole: Administration of Metronidazole 400mg tid for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin</title>
            <description>In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Clarithromycin: Administration of Clarithromycin 500mg bid for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance</title>
          <description>After 7 days of periodontal treatment, patients will be asked to return any medication not taken and/or the empty bottles. The number of pills not taken by the subject will be documented in order to evaluate compliance.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of patients that did not take ≥1 pills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of patients that interrupted the drug intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Effects That May be Related to Antibiotic Treatment</title>
        <description>Patients will be instructed to fill a self-report form about any possible adverse effects in order to help evaluate their adherence to the systemic antimicrobial regimen.</description>
        <time_frame>One week post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin and Metronidazole</title>
            <description>In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Amoxicillin: Administration of Amoxicillin 500mg tid for 7 days.&#xD;
Metronidazole: Administration of Metronidazole 400mg tid for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin</title>
            <description>In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Clarithromycin: Administration of Clarithromycin 500mg bid for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects That May be Related to Antibiotic Treatment</title>
          <description>Patients will be instructed to fill a self-report form about any possible adverse effects in order to help evaluate their adherence to the systemic antimicrobial regimen.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metallic taste</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea/abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin wounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during 7 days post-treatment</time_frame>
      <desc>7 days after the therapy patients returned to fill out a self-report form about 8 possible adverse effects resulting from the antibiotic intake, based on Martys: Headache, Stomach pain, Nausea/vomiting, Metallic taste, Diarrhea/ abdominal pain, Drowsiness, Itching and Skin wounds.</desc>
      <group_list>
        <group group_id="E1">
          <title>Amoxicillin and Metronidazole</title>
          <description>In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Amoxicillin: Administration of Amoxicillin 500mg tid for 7 days.&#xD;
Metronidazole: Administration of Metronidazole 400mg tid for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Clarithromycin</title>
          <description>In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.&#xD;
Full-mouth ultrasonic debridement: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites&#xD;
Clarithromycin: Administration of Clarithromycin 500mg bid for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhea/ abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Metallic taste</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Skin wounds</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Mauro Pedrine Santamaria</name_or_title>
      <organization>São Paulo State University - Unesp</organization>
      <phone>+5516981937777</phone>
      <email>mauro.santamaria@unesp.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

